According to FutureWise analysis the market for biologics contract manufacturing demand in 2023 was US$ 17.41 billion, and is expected to reach US$ 39.31 billion by 2031 at a CAGR of 10.72%. Biologics contract manufacturing is a vital part of the biopharmaceutical industry, focusing on the outsourcing of the production of complex biologic drugs, including monoclonal antibodies, vaccines, and...